share_log

Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20

Benzinga ·  Aug 8 00:19  · Ratings

Goldman Sachs analyst Corinne Jenkins maintains TG Therapeutics (NASDAQ:TGTX) with a Neutral and raises the price target from $18 to $20.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment